All products are for laboratory research use only. Not for human consumption.
Growth Hormone · Anabolic Potentiator
The Long-Acting Growth Factor
RM 790
Awaken profound renewal. IGF-1 LR3 1 mg is a master architect, signaling deep cellular regeneration for a visibly firmer, more youthful foundation.
For research use only. Not for human or veterinary consumption. This product is not a medicine and is not intended to diagnose, treat, cure or prevent any disease.
Overview
IGF-1 LR3 has two key modifications: an arginine substitution at position 3 (instead of glutamic acid) and 13 additional amino acids at the N-terminus. These changes dramatically reduce binding to IGF binding proteins (IGFBP), extending active half-life from 20 minutes to 20-30 hours. The result is virtually all circulating peptide remaining bioavailable — versus just 5% free for native IGF-1.
Mechanism of action
Complete IGF-1R signaling — identical to native IGF-1 at the receptor
Arg3 substitution eliminates binding protein sequestration
Protein synthesis, anti-catabolism, and anabolic pathway activation
Key finding IGF-1 LR3 retains full pharmacological activity at the IGF-1 receptor while having very low affinity for IGFBPs. This translates to approximately 3 times greater potency and a half-life of 20-30 hours (vs 12-15 hour half-life of regular IGF-1).
Key research findings
Greater potency versus native IGF-1 in muscle protein synthesis models due to reduced IGFBP binding
Tomas FM et al. J Endocrinol, 1992Increase in intestinal mass in animal model studies — demonstrates potent anabolic signaling across tissue types
Lemmey AB et al. Am J Physiol, 1997IGF-1 LR3 reduces protein catabolism 3-fold versus control in glucocorticoid-treated animal models
Tomas FM et al. Biochem J, 1993IGF-1 LR3 produced >8g body weight gain over 11 days versus control in animal growth studies
Tomas FM et al. J Endocrinol, 1992Research areas
The most potent available form of IGF-1 for muscle protein synthesis and hypertrophy research.
IGF-1R activation drives growth and repair across multiple tissue types — LR3 provides extended duration of this effect.
IGF-1 is a critical neurotrophic factor — LR3 extends its neuroprotective action duration significantly.
Extended half-life makes IGF-1 LR3 uniquely effective in anti-catabolic research — glucocorticoid-induced muscle wasting models.
Safety profile
Safety data is limited to preclinical animal studies. There are no human safety data. The following is extrapolated from research with native IGF-1 and observations in animal models.
Because IGF-1 LR3 is ~3x more potent than native IGF-1, all potential effects can be amplified — design protocols accordingly
IGF-1 has insulin-like activity — monitor blood glucose in research models
IGF-1 promotes sodium and water retention at higher doses
Excessive IGF-1 can cause acromegalic changes — dose carefully in sensitive models
Molecular profile
Frequently asked questions
Native IGF-1 is a 70 amino acid endogenous protein. IGF-1 LR3 adds 13 amino acids at the N-terminus and substitutes arginine for glutamic acid at position 3. These changes reduce IGFBP binding by 100-1000x, extending active half-life from 20 minutes to 20-30 hours. The receptor binding and downstream signaling are identical to native IGF-1.
In circulation, 95% of native IGF-1 is sequestered by IGF Binding Proteins (IGFBPs) — only 5% is free and bioavailable at any given time. The LR3 modification reduces IGFBP affinity dramatically, meaning most circulating IGF-1 LR3 is free to bind IGF-1 receptors. This translates to approximately 3x greater effective potency despite identical receptor binding.
No human clinical trial data is currently available for IGF-1 LR3 specifically. There is extensive animal study data, and native IGF-1 has been studied in humans. The pharmacology and safety should be extrapolated from native IGF-1 literature, accounting for LR3’s increased potency and extended duration.
Key animal model findings include: 2.5x greater protein synthesis vs native IGF-1; >8g body weight gain over 11 days vs control; 3x protein conservation in glucocorticoid-induced catabolic models; and significant intestinal growth. These findings establish LR3’s anabolic potency across multiple tissue types.
Yes. IGF-1 LR3 is prohibited by WADA under category S2 (Peptide Hormones, Growth Factors, Related Substances and Mimetics), both in and out of competition. This product is for research use only.
Lyophilized IGF-1 LR3 can be stored at 2-8°C or -20°C for up to 24 months. After reconstitution, store at 2-8°C and use within 2-4 weeks. Avoid repeated freeze-thaw cycles. Do not use if the solution appears cloudy or contains particles.
References
